

# SJVIA

# 2019 Pharmacy Audit Results



July 9, 2020 2019 Audit Results

#### **EXECUTIVE SUMMARY**

Keenan Pharmacy Services (KPS) conducted a financial audit of the clinical savings, discount performance, and rebates earned for SJVIA's 2019 contract year.

KPS audit findings resulted in a revised reconciliation from EmpiRx to adjust the AWP discount performance.

The clinical guarantee overperformed by \$3,103,543, offsetting the discount shortfall of \$1,415,348 and rebate withheld of \$445,915.

EmpiRx has met their contractual obligations for 2019 and no money is due to SJVIA for the 2019 contract year.



Client: SJVIA

Time Period: 1/1/2019 - 12/31/2019

\$1,110,000
\$4,213,543.36
\$3,103,543.36
(\$1,415,348.19)
\$2,229,577.00
20%
\$1,783,661.60
\$0
\$166.92
\$164.24
-1.6%
\$134.11
\$132.50
-1.2%
\$116.38
\$49.77
-57.2%

July 9, 2020 2019 Audit Results

#### AUDIT OBJECTIVE

KPS conducts a yearly financial audit of EmpiRx Clinical savings, Average Wholesale Price (AWP) discounts and Rebate performance against the client's aggregate contractual guarantees.

#### METHODOLOGY

- KPS conducts its financial analysis utilizing EmpiRx data feed received monthly.
- ♦ Claims and cost were assessed for a one-year period 1/1/2019 12/31/2019.
- EmpiRx contractual exclusions were excluded from calculations for the AWP and Rebate review.
- Per the contractual terms, any clinical savings achieved over the clinical guarantee can be used to offset any shortfalls in the performance of AWP discounts and dispensing fees.

# **AUDIT COMPONENTS**

### A. CLINICAL AUDIT

#### **Audit Parameters:**

- EmpiRx provided a clinical tracker with the details of claims, savings, and type of clinical intervention.
- KPS validated the cost savings using the following methodology for each intervention type\*.
  - Verified claims provided in clinical tracker existed within KPS data records.
  - Identified calculated savings versus discontinued claims.
  - Calculated savings was conducted at each claim level to ensure the savings illustrated from EmpiRx were accurate.

#### Audit Result:

Variance of \$4.89 attributed to rounding.

EmpiRx Clinical Type	Claims	KPPC Clinical Savings	EmpiRx Clinical Savings	Clinical Savings Variance	
CR	1	\$453.60	\$453.60	\$0.00	
DUR	478	\$109,148.34	\$109,147.97	\$0.41	
PA	843	\$1,953,642.57	\$1,953,640.73	\$1.93	
QL	2,458	\$1,181,163.00	\$1,181,161.85	\$1.25	
ST	1,148	\$969,140.35	\$969,139.21	\$1.30	
Total	4,928	\$4,213,547.87	\$4,213,543.36	\$4.89	

<sup>\*</sup>Interventions: Clinical Review (CR), Drug Utilization Review (DUR), Prior Authorization (PA), Quantity Limit (QL), Step Therapy (ST).

#### EmpiRx Adjustment:

♦ None

July 9, 2020 2019 Audit Results

#### B. AWP DISCOUNT AUDIT

#### **Audit Parameters:**

- Categorized claims by channel and brand/generic status
- EmpiRx Brand/Generic validated against Medispan multi-source code
- EmpiRx exclusion list provided was audited against contractual exclusion parameters for each category
  - Compound
  - Direct Member Reimbursement
  - Dosage Form
  - Drug Not Covered
  - Limited Distribution Drugs
  - Medicaid
  - Most Favored Nation
  - OTC or Device (Non-Diabetic)
- Acute Medications (non-annualized) with manual adjustments
- Clinical Savings (non-annualized) with manual adjustments
- Contractual guaranteed discounts calculated to determine overage/shortfall dollars for each category

#### Audit Result:

- Variance of 134 claims and \$89,599 identified
- Claims filled in 2019 and paid in 2020 were previously excluded

Channel	Туре	Claims	AWP	Ingredient Cost	Discount Achieved	Guaranteed Discount	Guarantee Overage/Shortfall \$	EmpiRx Reported \$	KPS vs. EmpiRx Difference \$	EmpiRx Reported Claims	Claims Difference
Retail	Brand	11,738	\$5,544,022.46	\$4,691,289.52	15.38%	16.75%	(\$75,890.82)	(\$75,866.40)	(\$24.42)	11,717	(21)
Retail	Generic	66,401	\$8,137,103.08	\$2,463,707.68	69.72%	80.00%	(\$836,287.06)	(\$832,199.17)	(\$4,087.89)	66,297	(104)
Retail 90	Brand	3,557	\$4,069,663.52	\$3,217,766.32	20.93%	22.50%	(\$63,777.09)	(\$63,798.41)	\$21.32	3,556	(1)
Retail 90	Generic	25,218	\$8,381,152.21	\$1,773,477.18	78.84%	83.00%	(\$348,681.30)	(\$345,482.39)	(\$3,198.91)	25,213	(5)
Specialty Retail	Brand	399	\$1,678,149.37	\$1,459,753.45	13.01%	21.00%	(\$134,015.45)	(\$62,605.48)	(\$71,409.97)	398	(1)
Specialty Retail	Generic	238	\$242,161.12	\$88,249.29	63.56%	21.00%	\$103,057.99	\$113,349.75	(\$10,291.76)	238	-
Mail	Brand	123	\$181,179.43	\$144,943.57	20.00%	24.00%	(\$7,247.20)	(\$7,247.20)	(\$0.00)	123	-
Mail	Generic	712	\$305,978.62	\$79,867.65	73.90%	89.00%	(\$46,210.00)	(\$46,191.79)	(\$18.21)	712	-
Specialty Mail	Brand	825	\$3,543,293.37	\$2,940,933.77	17.00%	21.00%	(\$141,732.01)	(\$141,142.39)	(\$589.62)	823	(2)
Specialty Mail	Generic	278	\$544,217.59	\$294,497.13	45.89%	21.00%	\$135,434.76	\$135,434.76	\$0.00	278	-
Grand Total	al	109,489	\$32,626,920.76	\$17,154,485.56	_		(\$1,415,348.19)	(\$1,325,748.72)	(\$89,599.47)	109,355	(134)

#### EmpiRx Adjustment:

EmpiRx adjusted reconciliation to account for KPS findings

2019 Audit Results July 9, 2020

## C. REBATE AUDIT

#### **Audit Parameters:**

- Claims were categorized by channel and brand/generic status
- EmpiRx Brand/Generic validated against Medispan multi-source code
- EmpiRx exclusion list provided was audited against contractual exclusion parameters for each category
  - Compound
  - Dosage Form
  - Drug Not Covered
  - Limited Distribution Drugs
  - Medicaid
  - OTC or Device (Non-Diabetic)
- ♦ Contractual guaranteed rebates calculated to determine earned amount

#### Audit Result:

Review and approved

Channel	Туре	Q1	Q2	Q3	Q4	Total Claims	Rebate Guarantee	Rebates Earned
Retail	Brand	2,647	2,580	2,722	2,854	10,803	\$69.00	\$745,407.00
Specialty Retail	Brand	98	103	92	99	392	\$69.00	\$27,048.00
Retail 90	Brand	822	877	857	878	3,434	\$173.00	\$594,082.00
Mail	Brand	27	28	35	32	122	\$210.00	\$25,620.00
Specialty Mail	Brand	160	209	227	225	821	\$1,020.00	\$837,420.00
Total		3,754	3,797	3,933	4,088	15,572		\$2,229,577.00

#### EmpiRx Adjustment:

♦ None